Cyxone starts in-human testing of its multiple sclerosis drug candidate

Swedish biotech company focused on autoimmune diseases, Cyxone is testing its drug candidate T20K, its first-in-human, phase I, clinical trial, for the treatment of multiple sclerosis (MS).

Cyxone’s application to start a first-in-human, phase I, trial with their prophylactic drug candidate T20K targeting multiple sclerosis (MS) has been approved by the accredited Ethics Committee and Central Commission on Research Involving Human Subjects (CCMO) in the Netherlands.

Currently, the focus is the recruitment and screening of healthy male volunteers for the study, the company said, noting that the first-in-human study with T20K is a double-blinded, singled center study in the Netherlands, where T20K will be administrated to healthy male volunteers through infusion.

Furthermore, the study will assess the level of T20K in the blood after administering one or two doses of the substance.

Kjell G. Stenberg, CEO of Cyxone, said that the start of our first-in-human trial for T20K is a big moment for Cyxone. “With T20K’s natural origin and excellent preclinical safety profile, we look forward to evaluating our candidate’s safety in humans and take another step forward towards transforming the treatment of autoimmune diseases,” Stenberg said.

Cyxone reminded in the press release that clinical phase I study is currently in the recruitment and screening stage, and is expected to be finished in the second half of 2019.